NCT01963260View on ClinicalTrials.gov

Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

April 26, 2015

Study Completion Date

April 26, 2015

Conditions
Immune Thrombocytopenia Purpura
Interventions
DRUG

MK-8723

MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.

DRUG

Matching Placebo

Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01963260 - Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) | Biotech Hunter | Biotech Hunter